Navigation Links
Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
Date:3/27/2008

- Composition of Matter Patent Granted and Enforceable in 24 European

Countries - Competitors Precluded from Immediate Commercialization of Competitive

Products

LAVAL, QC, March 27 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) announces that the European Patent Office (EPO) granted on May 31st 2007 Neptune's composition of matter patent entitled "Natural Marine Source Phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications" (EP01417211B1) and that this patent has now been issued and validated in twenty-four European countries.

This patent is directed to the use of Neptune marine phospholipid and flavonoid compositions as a medicament for the prevention and treatment of multiple chronic health conditions, including coronary artery disease caused by hypercholesterolemia, peripheral vascular disease, neurodegenerative and other cognitive disorders.

"This composition of matter patent is a critical achievement that constitutes a key component for our commercial pharmaceutical development program," said Dr. Tina Sampalis, Chief Scientific Officer of Neptune. "Neptune's mission has always been the development of innovative pharmaceutical ingredients, and this patent is viewed as a vital element towards Neptune's pharmaceutical initiatives. Its enforcement is a major accomplishment and a step forward," she added.

As part of the EPO procedure, within a nine-month period following the date of granting of the European patent, a notice of opposition can be filed in writing with the EPO. In the case of Neptune, oppositions were filed by Norway-based Aker BioMarine and Israel-based Enzymotec. The opposition proceedings are a multi-year (5-7 year) procedure with the potential outcome of maintaining the patent, amending it or, in certain cases, revoking it. According to EPO regulations,
'/>"/>

SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neptune Technologies expands into medicinal markets in Asia Pacific
2. Neptune Technologies receives GRAS notification in the United States
3. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
6. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
7. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
8. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
9. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
10. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
11. Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient Outcome ... myPROpad™ ePRO tablet with the addition of a touchscreen ... widely used and well-respected Patient Reported Outcome (PRO) instruments ... used during clinical trials and in other health care ... to demonstrate Health-Related Quality of Life outcomes (HRQoL) resulting ...
(Date:8/19/2014)... Shimadzu Scientific Instruments has introduced two ... adding to the company’s extensive line-up of HPLC ... operating environment, and full automation, the i-Series provides ... conventional to ultra-high-speed analysis. , The ... so users can begin building the lab of ...
(Date:8/19/2014)... 2014 Cellgen Diagnostics ... to fund a corporate lab for its genetic-based ... development is a critical component in the move ... the implementation of personalized medicine – a more ... , Indiegogo contributions will support Cellgen’s intent to ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
Breaking Biology Technology:EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... ROCKVILLE, Md., Aug. 3, 2011 Neuralstem, Inc. (NYSE ... U.S. Department of Defense (DOD) contract to develop its ... cancerous brain tumors. The research contract, entitled "Research to ... be carried out in collaboration with Principal Investigator John ...
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today ... Monday, August 8, 2011, after the U.S. financial markets close. ... on Monday, August 8, 2011, at 5:00 p.m. Eastern Daylight ... highlights.  A live webcast of the call will be available ...
... CAMBRIDGE, Mass., Aug. 2, 2011 Pathogenica, Inc. announced ... is speaking today at the IBC Life Sciences Drug ... During the conference, the only event on the ... development, and patient care, Dr. Doran will speak on ...
Cached Biology Technology:Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 3Anadys Pharmaceuticals to Report Second Quarter 2011 Financial Results 2Pathogenica CSO Speaks at IBC Life Sciences Drug Discovery & Diagnostic Development Week 2
(Date:8/20/2014)... have developed methods for electronically manipulating the flight muscles ... use to control those muscles. The work opens the ... for use in emergency response. , "In the big ... the movement of moths for use in applications such ... an assistant professor of electrical and computer engineering at ...
(Date:8/20/2014)... , Aug. 20, 2014  The second ... place in Tampa, Florida ... sessions with Steven Rahman, Director, Technology and Strategy at ... at Experian. The theme of this year,s event ... Privacy. "Biometrics UnPlugged: Mobility at ...
(Date:8/19/2014)... supermarkets to encourage healthier spending habits? A new study ... question by tracking the purchasing records in a supermarket ... the nutritional value of foods for sale. , The ... PhD, and Brian Wansink PhD, author of Slim by ... Hannaford Supermarkets in the Northeastern United States between January ...
Breaking Biology News(10 mins):Research paves way for development of cyborg moth 'biobots' 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... called ,pestilences, three are historically recognized as due to ... 19th to 21st centuries AD there were microbiological evidences ... pestis . "For a long time scholars from different ... of the past pandemics. Only ancient DNA analyses carried ...
... , May 9, 2013 Wexford Science & ... in the Wake Forest Innovation Quarter , today ... buildings currently underway represents an additional $150 million investment ... Wexford,s total investment in the Innovation Quarter to more ...
... NY and San Diego, CA A large, multi-institutional research ... a sweeping analysis in the current issue of the journal ... off to direct early human development. Led by Bing Ren ... The Salk Institute for Biological Studies and James Thomson of ...
Cached Biology News:Scientists confirm that the Justinianic Plague was caused by the bacterium Yersinia pestis 2Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter 2Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter 3Mapping the embryonic epigenome 2Mapping the embryonic epigenome 3
... enables sensitive, fast and specific detection of ... Short hybridisation time ( ... spreads Multiplex capability Available with ... Probes available with different labels. ...
... Source rat adult and fetal ... $550.00, * T75 plated cells ... * This product requires Celprogen ... M55007-08 and extracellular matrix, * ...
... Isolation Kit provides a rapid method for ... from the various bacterial species found within ... of genomic DNA from both gram negative ... ,Purification is based on spin column ...
...
Biology Products: